Alan Boobis received a Bachelor's degree in pharmacology in 1971 and his PhD degree in pharmacology in 1974, both from the University of Glasgow (UK).  Professor Boobis then worked as a Fogarty Visiting Fellow for two years with Dr Dan Nebert at the National Institutes of Health (Bethesda, MD). In 1976 he joined the department of Clinical Pharmacology at what was then the Royal Postgraduate Medical School (London, UK), as an MRC research training fellow and was appointed to a tenured lectureship in 1979.  He was subsequently promoted to Professor of Biochemical Pharmacology, his current position (in the Department of Medicine, at what is now Imperial College London). He is currently also director of the Health Protection Agency Toxicology Unit. His research interests include mechanistic toxicology, drug metabolism, risk assessment methodology and inflammatory lung disease, using PET imaging. He has published over 220 original research papers.  He was Editor-in-Chief of Food and Chemical Toxicology and is now emeritus editor. He has served as chairman of the British Toxicology Society and as president of EUROTOX.  He is an honorary member of EUROTOX and received their Merit Award in 2009.  He is a member and/or chair of a number of national and international scientific advisory committees, including several WHO IPCS working groups, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) (residues of veterinary drugs), the Joint FAO/WHO Meeting on Pesticide Residues (JMPR), the UK Committees on Carcinogenicity and on Toxicity, and the EFSA Panel on Contaminants in the Food Chain.  He is a member and past chairman of the Board of Trustees of ILSI HESI, a member of the Board of Trustees of ILSI and the Board of Directors of ILSI Europe. He is involved in several HESI and ILSI Europe projects. He is a fellow of the Society of Biology and of the British Toxicology Society.  He received an OBE for his work on the risk assessment of pesticides in 2003.

Kevin Park is currently Professor of Pharmacology, Head of the School of Biomedical Sciences at the University of Liverpool and Director of the M.R.C. Centre for Drug Safety Sciences. 

Professor Park was awarded a Fellowship of the Royal College of Physicians in 2009 and is also a Commissioner on Human Medicines and a Fellow of the Academy of Medical Sciences.

He has authored over 400 peer-reviewed publications. He was a Wellcome Principal Research Fellow from 1989-1999. The over-riding theme of his work is bridging “molecule–to-man” and back again, that is, enabling the prediction of adverse drug reactions based on the chemical structure of the drug and the identification of susceptible individuals.

This work has been expanded by using pharmacogenomics and toxicogenomics to link findings in patients to the chemical structure of the drug.

The group are now in a position to provide solutions to adverse drug reactions through research in two areas: 1) improved drug design and 2) the delivery of individualised medicines.

Professor Park has received a number of honours and distinctions which include the B.P.S. Sandoz Prize for Pharmacology, the Pfizer Medal for Innovative Science, The SmithKline and Beecham Prize for Clinical Pharmacology, The Vane Prize for Drug Metabolism and The Werner Kalow Lectureship (Canada).

Dr. David J. Dix is Deputy Director of the U.S. Environmental Protection Agency’s National Center for Computational Toxicology (NCCT), at Research Triangle Park, NC, USA, where he is leading the development of high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. Prior to Deputy Director, Dr. Dix was a Research Biologist conducting research in reproductive, genomic and computational toxicology at EPA. Dr. Dix is an adjunct Associate Professor in the Department of Environmental Sciences and Engineering at the University of North Carolina at Chapel Hill. He earned his undergraduate degree in Biological Sciences from the University of Illinois at Chicago, a Ph.D. in Physiology from Rush University in Chicago, and completed postdoctoral training at the U.S. National Institute of Environmental Health Sciences. He has published over 100 articles, reviews, reports and book chapters, serves on several Editorial Boards, and has given numerous national and international presentations on his research.

Dr. Patrik Rydberg is associate professor at the department of molecular drug research at the University of Copenhagen. He has an M.Sc. in chemical engineering and a PhD in theoretical chemistry from Lund University. His diverse background including experiences ranging from analytical chemistry to quantum chemistry, is currently applied to research in the field of computational chemistry.

Since receiving his PhD, Patrik's research focus has been on drug metabolism mediated by the cytochromes P450 enzyme family. His recent work has bridged the gap between quantum chemical studies of reaction mechanisms and the prediction of drug metabolism using cheminformatics methods, resulting in the release of the SMARTCyp site-of-metabolism prediction software.

Ivan Rusyn is Professor with tenure in the Department of Environmental Sciences and Engineering in the School of Public Health at the University of North Carolina at Chapel Hill. He directs the Laboratory of Environmental Genomics and the Carolina Center for Computational Toxicology in the Gillings School of Global Public Health at UNC. He is a member of the Lineberger Comprehensive Cancer Center, Center for Environmental Health and Susceptibility, Bowles Center for Alcohol Studies, and the Carolina Center for Genome Sciences. Dr. Rusyn served on several committees convened by the US National Research Council and the WHO/IARC. Dr. Rusyn's laboratory has an active research portfolio funded by the National Institutes of Health and the US EPA with a focus on the mechanisms of action of environmental toxicants, the genetic determinants of the susceptibility to toxicant- induced injury, and computational toxicology. His laboratory applies molecular, biochemical, genetic and genomics approaches to understanding the mechanisms of environmental agent-related disease. His studies on health effects of environmental agents resulted in more than 105 peer-reviewed publications. Dr. Rusyn received his M.D. (with honors) from Ukrainian State Medical University in Kiev and his Ph.D. in Toxicology from UNC-Chapel Hill. He also trained at the University of Dusseldorf in Germany and at the Massachusetts Institute of Technology.

Hans Westerhoff holds the AstraZeneca Chair for Systems Biology at the University of Manchester (where he directs the Manchester Centre for Integrative Systems Biology and its Doctoral Training Centre), as well as the Chair for Microbial Physiology at the VU University Amsterdam and the Chair for Synthetic Systems Biology at the University of Amsterdam.  He has co-authored more than 500 articles, on molecular biochemistry and biophysics as well as on the emergence of important biological functions from biological interactions.  One book laid the fundamentals of realistic non equilibrium thermodynamics for biology, whilst others helped define systems biology and develop its philosophy.  He was one of the first to integrate theory, modeling and quantitative experimentation into bioenergetics, biochemistry and cell biology.  He now works towards integral understanding of the networks of living organisms in health and disease.
After completing his studies at the University of Amsterdam, Westerhoff held appointments at the University of Padova, at the National Institutes of Health in Bethesda, at the Netherlands Cancer Institute and at the University of Amsterdam, before assuming his present positions at the two universities in Amsterdam and at the University of Manchester.  Hans Westerhoff has been involved in many emerging systems biology programs, including the German (BMBF) Hepatosys, UK’s Integrative Systems Biology, Luxemburgs BIOLUXMP, Europe’s BioSim, NucSys and EC-MOAN, as well as the transnational SysMO and ERASysBio research programs. At present he is one of the four main coordinators of the EU flagship preprogram IT for the Future Of Medicine, where he is responsible for the Integration platform.  ITFoM aims to achieve truly individualized medicine in due course by making 7 billion mathematical/ICT models for the 7 billion individuals on the planet.  A revolutionary, new ICT will be put in place to overcome the otherwise insurmountable hurdles that make these aims impossible at present.

Kyle L. Kolaja, Ph.D., D.A.B.T., started out on the pre-med path but was sidetracked by a lifelong interest in finding out how and why things work as they do. Kyle graduated from Michigan State University with his bachelor’s degree then joined the Ph.D. program in Toxicology at IUSM. He graduated in 1996 with his Ph.D. and moved to a post-doc position at the University of Kansas Medical Center.

Today Kyle, now the Director of Early Safety and Investigative Toxicology in Roche’s Non- Clinical Safety, has earned a top honor as a Fellow of the Academy of Toxicological Sciences (ATS). This honor is held by less than five percent of ATS members and Kyle is among the youngest and is the first Roche scientist to achieve this recognition since 1995.

Professor Roland Wolf OBE, Director of the Biomedical Research Centre at the University of Dundee, has an international reputation for his work in the field of molecular pharmacology, specifically drug resistance in cancer patients. After working in West Germany, the USA and England, he headed the Imperial Cancer Research Fund's Medical Oncology Unit at the Western General Hospital in Edinburgh. In 1992, Professor Wolf relocated his molecular pharmacology group to Dundee, and in 1998 his discovery of the role played by a single gene in protection against cancer made international headlines. He has published over 380 papers in peer-reviewed scientific journals and is on the Board of Governors of two cancer charities. In 2001, Professor Wolf co-founded CXR Biosciences, a company specialising in developing drug safety programmes. A champion of the city and the quality of life to be found in Dundee, he has said 'It is coming to the point now where people who are given the choice of Dundee or Cambridge are heading for Dundee'.

Professor Roland Wolf was rewarded for his services to science with an OBE in the New Year’s Honours list 2010.

Hugo Kubinyi is a medicinal chemist with 35 years of industrial experience in Knoll and BASF AG, Ludwigshafen, Germany. From 1987 until his retirement, he was responsible for the Molecular Modelling, X-ray Crystallography and Drug Design group of BASF. From early 1998 Hugo was also responsible for Combinatorial Chemistry in the Life Sciences. He is associate Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. In 2006 he received the ACS Herman Skolnik Award in Chemoinformatics (CINF section, ACS) and in 2008 the Nauta Award in Pharmacochemistry (EFMC). His scientific work has resulted in more than 100 publications and seven books on QSAR, 3D QSAR, Drug Design, Chemogenomics, and Drug Discovery Technologies.

Professor Steve Oliver is the director of the Cambridge Systems Biology Centre at the University of Cambridge.
His areas of research include functional genomics and systems biology in the model organism Saccharomyces cerevisiae which he has worked on since the 1970s.In 1992 Oliver led the team which provided first complete sequence analysis of an entire chromosome from any organism. More recently he has also been involved in the creation of a robot scientist 'Adam' and has been awarded numerous research grants by the Biotechnology and Biological Sciences Research Council

Harvey Clewell is a Senior Investigator at the Hamner Institutes for Health Sciences.  He has gained an international reputation for his research on the application of Physiologically Based Pharmacokinetic (PBPK) modeling to chemical risk assessment and pharmaceutical safety assessment, having played a major role in the first uses of PBPK modeling by FDA, ATSDR, OSHA, and EPA.  He has a Masters in Chemistry from Washington University, St. Louis, and a PhD in Toxicology from the University of Utrecht.  His current research interests include PBPK modeling of early life exposures, computer simulation of drug-induced liver injury, the use of genomic dose-response information in risk assessment, and the use of in vitro data and biological modeling to perform in vitro to in vivo extrapolation in support of animal-free toxicity testing. 

Yuichi Sugiyama started working as the Head of Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Research Cluster for Innovation, Yokohama, Japan on April 1st 2012.
He was a Professor for the Department of Molecular Pharmacokinetics at the University of Tokyo from1991until March 2012 when he moved to RIKEN.

His work is internationally recognized by prestigious awards, including AAPS Distinguished Pharmaceutical Scientist Award, 2003, Scientific Achievement Award 2004 from the
"Pharmaceutical Society of Japan(PSJ), and the PSWC (Pharmaceutical Sciences World Conference) Research Achievement Award in 2007, FIP Hoest Madsen Gold Medal in 2009, "Medal with Purple Ribbon" given by Government in 2010 and B.Brodie Award from ASPET in 2012. According to a recent report of ISI Essential Science Indicators, Professor Sugiyama has been ranked as the top (#1) cited scientist in the field of Pharmacology & Toxicology. His original articles published in the past 10 years, between January 1997 and February 2007, have received the highest number of citations in this field.
He served as the chairman of Board of Pharmaceutical Sciences in FIP (2000-2004) and was also the president of both “International society for the study of xenobiotics (ISSX)” and “Japanese Society for Xenobiotic Metabolism and Disposition (JSSX)”.(2006-2007).

Geoff is Emeritus Professor of Clinical Pharmacology at the University of Sheffield, UK. He graduated in pharmacy (1964) with a Ph.D (1967) from the University of London. He was at the Virginia Mason Research Center (Seattle) and the Anesthesia Research Center, University of Washington (1968-72), before returning to the UK in 1972. He has published widely in the areas of pharmacokinetics, drug metabolism, pharmacogenetics, and the pharmacology of drugs used in anaesthesia. (“Highly Cited Author” − Pharmacology; Institute of Scientific Information). He was Chairman of the Editorial Board of the British Journal of Clinical Pharmacology from 1995-2002. He is an Expert Advisor to the Commission on Human Medicines UK; a Vice-President of the International Pharmaceutical Federation (FIP); advisor to the European Federation of Pharmaceutical Sciences (EUFEPS); a Councillor of the International Society for the Study of Xenobiotics (ISSX); and Founding Member and Elder of the African Society for Drug Metabolism and Development. Geoff has been a Visiting Professor at the Universities of Harvard, Cincinnati and Otago and at the US FDA. He is a Fellow of the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the Faculty of Pharmaceutical Medicine of the Royal College of Physicians UK, the British Pharmacological Society, the British Toxicological Society and the American College of Clinical Pharmacology.

Dr. Teri Klein is a senior scientist and project director for the Pharmacogenomics Knowledge Base project at Stanford University.
Teri’s research interests extend over the broad spectrum of pharmacogenetics, computational biology and bioinformatics. As well as the development of a pharmcogenetics knowledge base, applications include structure-function relationships, de novo modeling and the structural basis of disease.

Dr. Brennan is an American Board of Toxicology-certified scientist with over 10 years experience in the biopharmaceutical industry. As Director of Toxicology at GeneGo (a Thomson Reuters business), he is responsible for all safety assessment related development. Prior to joining GeneGo, he was Director of Molecular and Investigative Toxicology at Iconix Biosciences, and previously served as Associate Director of Pharmacology and Cell Biology at Cornerstone Pharmaceuticals in Stony Brook New York and as Senior Scientist OSI Pharmaceuticals in Farmingdale New York. Dr. Brennan holds a Bachelor’s in Biochemistry, and a Ph.D. in Chemistry from the University of Warwick, UK, and conducted post-doctoral research at the University of Manchester and at the Harvard School of Public Health before joining industry.